SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4560-4566. Prepublished online as a Blood First Edition Paper on August 28, 2007; DOI 10.1182/blood-2007-06-095265. This Article Full Text Full Text (PDF) Supplemental Appendix and Table All Versions of this Article: blood-2007-06-095265v1 110/13/4560    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Shaw, B. E. Articles by Petersdorf, E. W. Search for Related Content PubMed PubMed Citation Articles by Shaw, B. E. Articles by Petersdorf, E. W. Related Collections Immunobiology Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation Bronwen E. Shaw1,2, Theodore A. Gooley3, Mari Malkki3, J. Alejandro Madrigal1,4, Ann B. Begovich5, Mary M. Horowitz6, Alois Gratwohl7, Olle Ringdén8, Steven G. E. Marsh1,4, and Effie W. Petersdorf3,9 1 Anthony Nolan Research Institute, London, United Kingdom; 2 Section of Haemato-Oncology, Royal Marsden Hospital/Institute of Cancer Research, Surrey, United Kingdom; 3 Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA; 4 Royal Free and University College London Medical School, London, United Kingdom; 5 Roche Molecular Systems, Alameda, CA; 6 Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee; 7 Hematology Department, University Hospital Basel, Basel, Switzerland; 8 Division of Clinical Immunology, Karolinska University Hospital Huddinge, Stockholm, Sweden; and 9 Department of Medicine, University of Washington School of Medicine, Seattle Hematopoietic cell transplantation (HCT) from an HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 allele–matched unrelated donor is a well-recognized life-saving treatment modality for patients with hematologic disorders. The morbidity and mortality from clinically significant acute graft-versus-host disease (aGVHD) remains a limitation. The extent to which transplantation outcome may be improved with donor matching for HLA-DP is not well defined. The risks of aGVHD, relapse, and mortality associated with HLA-DPB1 allele mismatching were determined in 5929 patients who received a myeloablative HCT from an HLA-A–, HLA-B–, HLA-C–, HLA-DRB1–, and HLA-DQB1–matched or –mismatched donor. There was a statistically significantly higher risk of both grades 2 to 4 aGVHD (odds ratio [OR] = 1.33; P < .001) and grades 3 to 4 aGVHD (OR = 1.26; P < .001) after HCT from an HLA-DPB1–mismatched donor compared with a matched donor. The increased risk of aGVHD was accompanied by a statistically significantly decrease in disease relapse (hazard ratio [HR] = 0.82; P = .01). HLA-DPB1 functions as a classical transplantation antigen. The increased risk of GVHD associated with HLA-DPB1 mismatching is accompanied by a lower risk of relapse. Knowledge of the DPB1 matching status prior to transplantation will aid in more precise risk stratification for the individual patient. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020